The estimated Net Worth of Suzanne Sawochka Hooper is at least $6.64 millió dollars as of 25 February 2019. Ms. Hooper owns over 6,666 units of Ngm Biopharmaceuticals Inc stock worth over $71,462 and over the last 12 years she sold NGM stock worth over $5,840,766. In addition, she makes $730,348 as Independent Director at Ngm Biopharmaceuticals Inc.
Sign up
Ms. Hooper NGM stock SEC Form 4 insiders trading
Suzanne has made over 25 trades of the Ngm Biopharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently she exercised 6,666 units of NGM stock worth $312,169 on 25 February 2019.
The largest trade she's ever made was exercising 10,231 units of Ngm Biopharmaceuticals Inc stock on 11 May 2018 worth over $499,887. On average, Suzanne trades about 1,377 units every 35 days since 2012. As of 25 February 2019 she still owns at least 46,404 units of Ngm Biopharmaceuticals Inc stock.
You can see the complete history of Ms. Hooper stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Suzanne Hooper biography
Suzanne Sawochka Hooper J.D. serves as Independent Director of the Company. Ms. Hooper From March 2012 to March 2019, Ms. Hooper served as the Executive Vice President and General Counsel of Jazz Pharmaceuticals plc. From 1999 until February 2012, she was a partner in the law firm Cooley LLP. Ms. Hooper received a J.D. from the University of California Berkeley School of Law and a B.A. in Political Science from the University of California, Santa Barbara. Ms. Hooper is a member of the State Bar of California. In addition, Ms. Hooper’s experience as the Executive Vice President of a publicly-traded pharmaceutical company provided her with operational expertise that is important to our Board of Directors.
What is the salary of Suzanne Hooper?
As the Independent Director of Ngm Biopharmaceuticals Inc, the total compensation of Suzanne Hooper at Ngm Biopharmaceuticals Inc is $730,348. There are 3 executives at Ngm Biopharmaceuticals Inc getting paid more, with David Woodhouse having the highest compensation of $2,092,150.
How old is Suzanne Hooper?
Suzanne Hooper is 54, she's been the Independent Director of Ngm Biopharmaceuticals Inc since 2018. There are 9 older and 8 younger executives at Ngm Biopharmaceuticals Inc. The oldest executive at Ngm Biopharmaceuticals Inc is David Goeddel, 68, who is the Lead independent director.
What's Suzanne Hooper's mailing address?
Suzanne's mailing address filed with the SEC is C/O NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Ngm Biopharmaceuticals Inc
Over the last 6 years, insiders at Ngm Biopharmaceuticals Inc have traded over $9,159,599 worth of Ngm Biopharmaceuticals Inc stock and bought 18,889,291 units worth $177,396,366 . The most active insiders traders include Peter Svennilson, David V Goeddel és Group L P Svennilson Peter .... On average, Ngm Biopharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $171,092. The most recent stock trade was executed by Group L Ptcg Opportunity Ii... on 15 November 2023, trading 22,631 units of NGM stock currently worth $15,615.
What does Ngm Biopharmaceuticals Inc do?
ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work
What does Ngm Biopharmaceuticals Inc's logo look like?
Complete history of Ms. Hooper stock trades at Jazz Pharmaceuticals plc, Eidos Therapeutics Inc és Ngm Biopharmaceuticals Inc
Ngm Biopharmaceuticals Inc executives and stock owners
Ngm Biopharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
David Woodhouse,
Chief Executive Officer, Director -
Jin-Long Chen,
Founder, Chief Scientific Officer, Director -
William Rieflin,
Executive Chairman of the Board of Directors -
Suzanne Hooper,
Independent Director -
Dr. David J. Woodhouse Ph.D.,
CEO & Director -
Dr. Jin-Long Chen Ph.D.,
Founder, Chief Scientific Officer & Director -
Shelly Guyer,
Independent Director -
Siobhan Nolan Mangini,
CFO and Principal Financial & Accounting Officer -
McHenry Tichenor,
Independent Director -
David Goeddel,
Lead independent director -
David Schnell,
Independent Director -
Mark Leschly,
Independent Director -
William J. Rieflin J.D.,
Exec. Chairman of Directors -
Siobhan Mangini,
Chief Financial Officer -
Carole Ho,
Independent Director -
Hsiao Lieu,
Senior Vice President, Chief Medical Officer -
Marc Learned,
Vice President - Research Operations -
Hui Tian,
Senior Vice President - Research -
Wenyan Shen,
Senior Vice President - Biologics and CMC -
Alex DePaoli,
Senior Vice President, Chief Translational Officer -
Valerie Pierce,
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary -
Dr. Hsiao Dee Lieu,
Chief Medical Officer & Sr. VP -
Brian Muma,
VP of HR -
Valerie L. Pierce J.D.,
Sr. VP, Gen. Counsel, Sec. & Chief Compliance Officer -
Alexander Duke Schwartz,
Exec. Director of Investor Relations -
Group L Ptcg Opportunity Ii...,
-
Group L Pcolumn Group Gp, L...,
-
Group L Pcolumn Group Gp, L...,
-
Group L P Svennilson Peter ...,
-
Peter Svennilson,
Director -
Group L Pcolumn Group Ii, L...,
-
Group L Pcolumn Group Iii, ...,
-
Aetna Wun Trombley,
President & COO -
Group L Pcolumn Group Ii, L...,
-
Group L Pcolumn Group Ii, L...,
-
Group L P Ponoi Capital Ii,...,
-
Group L Pcolumn Group Iii, ...,
-
Roger M Perlmutter,
-
Group L Pcolumn Group Gp, L...,
-
Group L Pcolumn Group Iii, ...,
-
Jean Frederic Viret,
Chief Financial Officer -
Group Gp, Lpcolumn Group Ii...,
-
Opportunity Iii Gp, Llc Tcg,
10% owner -
Irene Perlich,
Principal Accounting Officer